Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases. Our lead cell therapy is FDA IND cleared next generation CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2 NEXICART-1 (NCT04720313) clinical trial, initiated in February 2021. NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients and supporting ongoing expansion into autoimmune indications. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (EMA) in AL Amyloidosis. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Company Details
- Employees
- 25
- Founded
- -
- Address
- Los Angeles, Los Angeles,ca 90064,united States
- Phone
- (888) 958-1084
- in****@****bio.com
- Industry
- Biotechnology
- Website
- immixbio.com
- HQ
- Los Angeles, CA
Immix Biopharma (Nasdaq: Immx) Questions
Immix Biopharma (Nasdaq: Immx)'s helpline number is (888) 958-1084
Immix Biopharma (Nasdaq: Immx)'s website is immixbio.com
Immix Biopharma (Nasdaq: Immx)'s LinkedIn profile is https://www.linkedin.com/company/immix-biopharma
Immix Biopharma (Nasdaq: Immx) has
25 employees.
View email and phone details for 25
employees at Immix Biopharma (Nasdaq: Immx).
Immix Biopharma (Nasdaq: Immx)'s industry is
Biotechnology
Immix Biopharma (Nasdaq: Immx)'s top competitors are
Iovance Biotherapeutics, Inc.,
Atengen, Inc.,
Amgen,
Alnylam Pharmaceuticals,
Arrowhead Pharmaceuticals,
Gilead Sciences,
Nexcella, Inc.,
Kyverna Therapeutics,
Cellenkos, Inc.,
Crinetics Pharmaceuticals.
Immix Biopharma (Nasdaq: Immx)'s support email address is info@immixbio.com
Immix Biopharma (Nasdaq: Immx)'s categories are Biotechnology
Immix Biopharma (Nasdaq: Immx)'s founding year is 2012
